comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Association of glucagon-like peptide-1 receptor in type 2 diabetic kidney transplant recipients | Cardiovascular Diabetology SGLT2 vs GLP-1: Individualizing Diabetes,
Description
The combination addresses both limitations simultaneously
Hold the syringe under your thumb and first finger
The abdomen is generally the most accessible site for self-injection
Newer JAK inhibitors (e.g., upadacitinib) are also available for certain patients
You may see little or no results and find yourself disappointed or, worse, lulled into a false sense of security
